Interim report
Page 1
RNS Number : 3228UIntegrated Diagnostics Holdings PLC11 September 2026 Integrated Diagnostics Holdings Plc1H 2026 ResultsFriday, 11 September 2026 Integrated Diagnostics Holdings plc reports 37% revenue growth in1H 2026, supported by broad-based expansion across core marketswith sustained profitability (London) - Integrated Diagnostics Holdings ("IDH," "the Group," or "the Company"), a leading provider of diagnostic services with operations in Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan, announced today its unaudited financial results for the six-month period ended 30 June 2026. The Company reported revenues of EGP 4.9 billion in 1H 2026, representing a 37% year-on-year increase, driven by a 20% rise in tests performed and a 14% increase in average revenue per test, reflecting continued growth in patient volumes, stronger service utilisation, and improved value capture across the Group's footprint. Gross profit increased 41% year-on-year to EGP 2.1 billion, while EBITDA grew 38% year-on-year to EGP 1.6 billion, resulting in an EBITDA margin of 33.9%. Net profit rose 47% year-on-year to EGP 839 million in 1H 2026. Excluding foreign exchange gains/losses in both periods, adjusted net profit increased 40% year-on-year to EGP 802 million, with the associated margin improving to 16.5%. On a quarterly basis, IDH delivered revenues of EGP 2.8 billion in Q2 2026, up 42% year-on-year from EGP 2.0 billion in Q2 2025. Gross profit increased 51% year-on-year to EGP 1.3 billion, with the gross profit margin expanding to 46.6% from 43.8% in the prior-year quarter. EBITDA increased 50% year-on-year to EGP 1.0 billion, yielding an EBITDA margin of 37.2% compared with 35.3% in Q2 2025. Net profit increased 23% year-on-year to EGP 402 million, despite the impact of higher foreign exchange losses during the quarter. Excluding foreign exchange losses in both periods, adjusted net profit increased 42% year-on-year to EGP 510 million. Performance during the period reflected strong underlying demand across the Group's operating markets, supported by continued branch expansion, higher patient throughput across both contract and walk-in segments, and growing utilisation of specialised diagnostics and radiology services. While profitability continued to reflect the impact of planned growth investments, including the ramp-up of Biolab KSA and continued expansion of the radiology platform, the Group maintained healthy margins supported by disciplined cost management, procurement optimisation, and operational execution. During the period, IDH's shareholder structure evolved following a mandatory cash offer launched by Hena Holdings Ltd, the Company's founding shareholder vehicle, which is wholly owned by IDH Chief Executive Officer Dr. Hend El-Sherbini and her mother, Dr. Moamena Abdul Wahab Kamel. On 23 June 2026, Hena Holdings announced the offer following its acquisition of 126 million shares from Actis IDH Limited, representing 21.67% of IDH's total voting rights. The transaction increased Hena Holdings' total shareholding to 49.62%, thereby triggering a mandatory takeover offer under the UK Takeover Code. Following the close of the initial offer period on 29 July 2026 and the expiry of the final two-week extension on 12 August 2026, Hena Holdings acquired additional shares through the offer, bringing its total ownership in IDH to 56.67%. Consequently, the remaining 43.33% of IDH's shares continue to be held by public shareholders, representing the Company's free float. Financial Results (IFRS) EGP mn Q2 2025 Q2 2026 Change 1H 2025 1H 2026 Change Revenue 1,960 2,783 42% 3,543 4,856 37% Cost of Sales (1,101) (1,486) 35% (2,053) (2,751) 34% Gross Profit 859 1,298 51% 1,489 2,105 41% Gross Profit Margin 43.8% 46.6% 2.8 pts. 42.0% 43.3% 1.3 pts. Operating Profit 556 868 56% 921 1,325 44% EBITDA 691 1,036 50% 1,190 1,647 38% EBITDA Margin 35.3% 37.2% 1.9 pts. 33.6% 33.9% 0.3 pts. Net Profit 326 402 23% 571 839 47% Net Profit Margin 16.6% 14.4% (2.2) pts. 16.1% 17.3% 1.2 pts. Adjusted Net Profit1 360 510 42% 575 802 40% Adjusted Net Profit Margin 18.4% 18.3% (0.1) pts. 16.2% 16.5% 0.3 pts. Cash Balance2 1,708 1,926 13% 1,708 1,926 13% Note: Throughout the document, percentage changes are calculated using the exact value (as per the Consolidated Financials) and not the corresponding rounded figure. [1] Adjusted net profit excludes foreign exchange gains/losses from all periods. In 1H 2026, IDH recorded a foreign exchange gain of EGP 36.9 million, compared with a foreign exchange loss of EGP 3.5 million in 1H 2025. On a quarterly basis, IDH recorded a foreign exchange loss of EGP 108.1 million in Q2 2026, compared with a foreign exchange loss of EGP 34.1 million in Q2 2025. 2 Cash balance includes time deposits, treasury bills, current accounts, and cash on hand. Key Operational Indicators3 EGP 1H 2025 1H 2026 Change
Page 2
Branches 678 8394 +161 Patients ('000) 4,265 4,861 14%Revenue per Patient (EGP) 831 999 20%Tests ('000) 19,619 23,629 20%Revenue per Test (EGP) 181 206 14%Test per Patient 4.6 4.9 6% 3 Key operational indicators are calculated based on revenue for the periods of EGP 4,856 million and EGP 3,543 million for 1H 2026 and 1H 2025, respectively. 4 During the twelve-month period, IDH rolled out 157 new branches in Egypt, two new branches in Jordan, and three new branches in KSA, while the Group's branch network inNigeria declined by one branch. Introduction i. Financial Highlights · IDH reported consolidated revenue of EGP 4,856 million in 1H 2026, representing a 37% year-on-year increase,driven by a 20% rise in test volumes and a 14% increase in average revenue per test (ARPT). Growth remainedbroad-based across the Group's footprint, with Egypt, Jordan, Nigeria, and Saudi Arabia all contributing positivelyduring the period. Performance was supported by continued expansion of the branch network, higher patientthroughput across both contract and walk-in segments, and growing utilisation of specialised diagnostics andradiology services. On a quarterly basis, consolidated revenue reached EGP 2,783 million in Q2 2026, up 42% year-on-year.· Gross profit reached EGP 2,105 million in 1H 2026, representing a 41% year-on-year increase, while the gross profitmargin (GPM) improved to 43.3%, compared with 42.0% in 1H 2025. Margin performance reflected strong operatingleverage on the back of higher volumes, continued procurement optimisation, and disciplined cost management.Raw materials as a share of revenue improved to 18.1% from 19.6% in 1H 2025, while direct wages and salaries,including employee profit share, remained stable at 19.1% of revenue in both periods, reflecting continuedefficiency gains despite ongoing branch expansion and investment in operational capacity. On a quarterly basis,gross profit increased 51% year-on-year to EGP 1,298 million in Q2 2026, with GPM expanding to 46.6% from 43.8%in Q2 2025.· EBITDA increased 38% year-on-year to EGP 1,647 million in 1H 2026, with an EBITDA margin of 33.9%, broadly inline with 33.6% in 1H 2025. Operating profit also recorded strong growth, increasing 44% year-on-year to EGP 1,325million, with the associated margin improving to 27.3% from 26.0% in the prior-year period. Profitability during thefirst half continued to benefit from stronger gross profitability, disciplined SG&A management, digitalisationinitiatives, and operating leverage across the platform, while ongoing investments in growth initiatives, particularlyin Saudi Arabia and radiology expansion, continued to support the Group's long-term growth trajectory. In Q2 2026,EBITDA increased 50% year-on-year to EGP 1,036 million, with the EBITDA margin expanding to 37.2% from 35.3% inQ2 2025.· Net profit rose 47% year-on-year to EGP 839 million in 1H 2026, with a net profit margin (NPM) of 17.3%, comparedwith 16.1% in 1H 2025. Excluding foreign exchange gains/losses in both periods, adjusted net profit increased 40%year-on-year to EGP 802 million, with the associated margin improving to 16.5% from 16.2% in 1H 2025, highlightingthe continued strength of the Group's underlying operating performance during the period. On a quarterly basis,net profit increased 23% year-on-year to EGP 402 million in Q2 2026, despite the impact of higher foreign exchangelosses during the quarter.· IDH's net cash balance stood at EGP 239 million as at 30 June 2026, compared with EGP 472 million as at 31December 2025, reflecting continued strong operating cash generation and disciplined working capitalmanagement.· Dividend Distribution: As indicated at the time of the FY 2025 ordinary dividend, the Board has continued toevaluate the scope for an additional distribution as market conditions and the Group's capital requirements haveevolved. Following this review, the Board considers it prudent to preserve cash and maintain balance sheetflexibility. This reflects both a number of well-defined expansion opportunities requiring capital and continuedgeopolitical uncertainty across the region, reinforcing the need for financial resilience and adequate USD liquidity.The Board believes this approach is in shareholders' best interests, preserving the flexibility to pursue valueaccretive growth opportunities, while remaining well positioned to withstand external volatility. ii. Operational Highlights · As at 30 June 2026, IDH's branch network stood at 839 branches, up 161 branches year-on-year from 678 branchesas at 30 June 2025. Over the past twelve months, the Group inaugurated 157 new branches in Egypt, two newbranches in Jordan, and three additional branches in Saudi Arabia, while the Nigerian network decreased by onebranch. Operations in Sudan remained largely suspended, with only one branch partially operational.· During 1H 2026, IDH conducted 23.6 million tests, representing a 20% year-on-year increase, supported by higherpatient throughput across both contract and walk-in channels. Test volumes increased across the Group's key operatinggeographies, with particularly strong momentum in Egypt and Saudi Arabia. Growth during the period underscores theresilience of underlying demand and the continued strength of the Group's brands across its footprint.· Average revenue per test (ARPT) increased 14% year-on-year to EGP 206 in 1H 2026, reflecting continued pricingoptimisation and a richer service mix supported by higher contributions from radiology, radiotherapy, andspecialised diagnostics. Average revenue per patient rose 20% year-on-year to EGP 999, highlighting IDH'scontinued success in enhancing value capture per patient through cross-selling initiatives, deeper service utilisation,and broader diagnostic offerings.· IDH served 4.9 million patients during 1H 2026, up 14% year-on-year. In parallel, the Group further improved itsaverage tests per patient metric to 4.9, compared with 4.6 in 1H 2025. This improvement reflects the effectivenessof IDH's ongoing efforts to deepen patient engagement, strengthen referral flows, and expand utilisation across itsintegrated diagnostics platform. iii. Updates by Geography · In Egypt (85.9% of total revenue in 1H 2026), IDH recorded revenues of EGP 4,170 million during the period,representing 41% year-on-year growth compared to 1H 2025. Growth was supported by a 21% increase in testvolumes alongside a 16% rise in average revenue per test, reflecting continued strength in underlying demand,pricing optimisation, and a richer service mix, including growing contributions from radiology, radiotherapy, and
Page 3
specialised diagnostics. Egypt also remained the Group's primary profitability driver, generating EBITDA of EGP 1,519million, up 42% year-on-year, with the EBITDA margin broadly stable at 36%.· IDH's Jordanian subsidiary, Biolab (11.1% of total revenues in 1H 2026), reported revenues of JOD 7.5 million, up 8%year-on-year from JOD 7.0 million in 1H 2025. In Egyptian pound terms, revenues increased 9% year-on-year to EGP537 million. Performance during the period was supported by a 10% increase in test volumes, while patients servedremained broadly stable, increasing 1% year-on-year, reflecting higher tests per patient and the continuedeffectiveness of Biolab's promotional, cross-selling, and loyalty initiatives. Average revenue per test in EGP termsdeclined slightly by 1% year-on-year, reflecting pricing dynamics within Jordan's regulated healthcare market. Biolabrecorded EBITDA of JOD 2.0 million during the period, broadly stable year-on-year, with an EBITDA margin of 26%,compared with 29% in 1H 2025.· In Nigeria (1.5% of total revenues in 1H 2026), Echo-Lab recorded revenues of NGN 2.0 billion, representing 12%year-on-year growth in local currency terms. In Egyptian pound terms, revenues increased 27% year-on-year to EGP73 million. Growth during the period was supported by continued pricing adjustments implemented to offset localinflationary pressures, with average revenue per test increasing 23% year-on-year, alongside a 3% increase in testvolumes. Importantly, Echo-Lab continued to build on its operational turnaround, generating positive EBITDA ofNGN 142 million in 1H 2026, compared with NGN 40 million in 1H 2025, with the EBITDA margin improving to 7%from 2% last year.· Biolab KSA, IDH's newest venture in Saudi Arabia (1.5% of total revenues in 1H 2026), reported revenues of SAR 5.5million during the period, representing 191% year-on-year growth compared with 1H 2025. In Egyptian poundterms, revenues increased 199% year-on-year to EGP 76 million. Growth was driven by strong increases in patienttraffic, up 144% year-on-year, and test volumes, up 194% year-on-year, following the expansion of the network tofive operational branches and reflecting growing brand awareness and continued ramp-up across the venture'soperations. Biolab KSA's EBITDA loss narrowed to SAR 1.2 million, compared with a loss of SAR 1.9 million in 1H2025, with the EBITDA margin improving significantly to negative 21% from negative 101%, reflecting strongerutilisation and early-stage operating leverage as the business continues to scale.· In Sudan, one branch remained partially operational throughout the period, while the remaining 17 branchescontinued to be closed indefinitely pending stabilisation of conditions in the country. Management continues toclosely monitor developments on the ground while prioritising the safety of employees and patients. iv. Management Commentary Commenting on the Group's 1H 2026 performance, IDH Chief Executive Officer, Dr. Hend El-Sherbini, said: "We are pleased to report a strong first-half performance, reflecting the continued resilience of demand across our markets, the strength of IDH's brands, and the scalability of our operating platform. During 1H 2026, revenues increased 37% year-on-year to EGP 4.9 billion, supported by a 20% increase in tests performed and a 14% rise in average revenue per test. This performance was broad-based, with Egypt, Jordan, Nigeria, and Saudi Arabia all contributing positively to growth, and underscores the importance of diagnostics as a core component of healthcare delivery across our footprint. Importantly, our top-line momentum translated into sustained profitability. Gross profit increased 41% year-on-year to EGP 2.1 billion, with gross profit margin expanding to 43.3%, supported by procurement optimisation, disciplined cost management, and stronger operating leverage as volumes grew. EBITDA increased 38% year-on-year to EGP 1.6 billion, with the EBITDA margin broadly stable at 33.9%, even as we continued to invest in long-term growth initiatives, including the ramp-up of Biolab KSA and the expansion of our radiology and radiotherapy platform. Net profit rose 47% year-on-year to EGP 839 million, while adjusted net profit, excluding foreign exchange gains and losses in both periods, increased 40% to EGP 802 million, highlighting the continued strength of the Group's underlying operating performance. Operationally, we continued to deepen our reach and strengthen utilisation across the platform. As at 30 June 2026, IDH operated 839 branches, up 161 branches year-on-year, with most of the expansion taking place in Egypt, alongside further additions in Jordan and Saudi Arabia. During the period, we served 4.9 million patients and performed 23.6 million tests, while average tests per patient increased to 4.9 from 4.6 in the prior-year period. This improvement reflects the effectiveness of our cross-selling initiatives, referral network, and broader service offering, as well as the growing role of specialised diagnostics, radiology, and radiotherapy within our portfolio. Egypt remained the Group's primary growth and profitability engine, delivering 41% revenue growth and EBITDA of EGP 1.5 billion, with margins remaining healthy at 36%. Growth was supported by continued demand across both contract and walk- in segments, pricing optimisation, and a richer service mix. Our radiology and radiotherapy platform also continued to scale, reinforcing our strategy of expanding into higher-value services that complement our core diagnostics offering and strengthen our position across the patient care pathway. Across our other markets, performance remained encouraging. In Jordan, Biolab continued to deliver stable growth in a regulated pricing environment, supported by higher test volumes, loyalty initiatives, and disciplined cost management. In Nigeria, Echo-Lab maintained its turnaround momentum, generating positive EBITDA and further improving margins, supported by pricing actions, cost rationalisation, and stronger utilisation. In Saudi Arabia, Biolab KSA continued to scale rapidly, with significant growth in patients and tests performed, while EBITDA losses narrowed materially as the business benefited from improved utilisation and early-stage operating leverage. In Sudan, our approach remains cautious and safety- led, with one branch partially operational while the broader network remains closed pending stabilisation. Looking ahead, our priorities remain clear. We will continue expanding access to high-quality diagnostics in structurally attractive markets, deepening our specialised service offering, and enhancing value per patient through a broader and more integrated platform. At the same time, we remain focused on operational efficiency, disciplined capital allocation, and maintaining the flexibility of our asset-light model. While we continue to monitor macroeconomic and regional developments closely, the progress achieved during the first half reinforces our confidence in IDH's ability to sustain growth, protect profitability, and deliver long-term value for patients, employees, and shareholders."
Page 4
Analyst and Investor Call Details An analyst and investor call will be hosted at 13:00 pm (UK) | 15:00 (Egypt) on Tuesday, 15 September 2026. You can learn more details and register for the call by clicking on the link. For more information about the event, please contact: amoataz@EFG-HERMES.com About Integrated Diagnostics Holdings (IDH) IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of clinical pathology andradiology tests to patients in Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan. The Group's core brands include Al Borg, AlBorg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Echo-Lab (Nigeria), Ultralab and Al Mokhtabar Sudan (bothin Sudan), and Biolab KSA (Saudi Arabia). With over 40 years of experience, a long track record for quality and safety hasearned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 3,000diagnostics tests. From its base of 839 branches as of 30 June 2026, IDH serves nearly 10 million patients and performs over40 million tests annually. IDH will continue to add laboratories through a Hub, Spoke and Spike business model that providesa scalable platform for efficient expansion. Beyond organic growth, the Group targets expansion in appealing markets,including acquisitions in the Middle Eastern, African, and East Asian markets where its model is well-suited to capitalise onsimilar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity (i) whose shares are admitted to the equity shares (transition) category (previously, the standard listingsegment) of the Official List of the UK Financial Conduct Authority and admitted to trading on the main market for listedsecurities of the London Stock Exchange (ticker: IDHC) since May 2015. Shareholder Information LSE: IDHC.L Bloomberg: IDHC:LN Listed on LSE: May 2015 Shares Outstanding: 581,326,272 Contact Mirette Ahmed Investment Section Head and IR Officer T: +20 (0)2 3332 1126 | M: +20 11 1784 7401 | mirette.ahmed@idhcorp.com Forward-Looking StatementsThese results for the six months ended 30 June 2026 have been prepared solely to provide additional information to shareholdersto assess the group's performance in relation to its operations and growth potential. These results should not be relied upon by anyother party or for any other reason. This communication contains certain forward-looking statements. A forward-looking statementis any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as"according to estimates", "aims", "anticipates", "assumes", "believes", "could", "estimates", "expects", "forecasts", "intends", "is ofthe opinion", "may", "plans", "potential", "predicts", "projects", "should", "to the knowledge of", "will", "would" or, in each casetheir negatives or other similar expressions, which are intended to identify a statement as forward-looking. This applies, inparticular, to statements containing information on future financial results, plans, or expectations regarding business andmanagement, future growth or profitability and general economic and regulatory conditions and other matters affecting theGroup. Forward-looking statements reflect the current views of the Group's management ("Management") on future events, which arebased on the assumptions of the Management and involve known and unknown risks, uncertainties and other factors that maycause the Group's actual results, performance or achievements to be materially different from any future results, performance orachievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of an assumptioncould cause the Group's actual financial condition and results of operations to differ materially from, or fail to meet expectationsexpressed or implied by, such forward-looking statements. The Group's business is subject to a number of risks and uncertainties that could also cause a forward-looking statement, estimateor prediction to differ materially from those expressed or implied by the forward-looking statements contained in thiscommunication. The information, opinions and forward-looking statements contained in this communication speak only as at itsdate and are subject to change without notice. The Group does not undertake any obligation to review, update, confirm or torelease publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relationto the content of this communication. Group Operational & Financial Review i. Revenue and Cost Analysis Consolidated Revenue IDH delivered strong top-line growth during 1H 2026, reporting consolidated revenues of EGP 4,856 million, representing a 37% year-on-year increase compared with 1H 2025. Growth was supported by a 20% increase in test volumes alongside a 14% rise in average revenue per test (ARPT), reflecting continued expansion in patient activity, improved service utilisation, and ongoing contributions from specialised diagnostics and radiology services across the Group's footprint. On a quarterly basis, consolidated revenue reached EGP 2,783 million in Q2 2026, representing a 42% year-on-year increasecompared with Q2 2025. The strong quarterly performance was supported by continued growth across both patientsegments, higher testing activity, and improved value capture across the Group's key markets following the seasonal impactrecorded during the first quarter of the year. 1H 2025 1H 2026 Change Revenue (EGP mn) 3,543 4,856 37%Tests performed (mn) 19.6 23.6 20%
Page 5
Revenue per test (EGP) 181 206 14% Revenue Analysis: Contribution by Patient Segment Contract Segment (69% of Group revenue in 1H 2026) Revenues from the contract segment reached EGP 3,355 million in 1H 2026, representing 41% year-on-year growth compared with EGP 2,383 million in 1H 2025. Growth was supported by a 20% increase in test volumes alongside an 18% rise in average revenue per test, reflecting continued strength across corporate, insurance, and referral channels. Average tests per patient in the contract segment increased to 5.1 tests per patient in 1H 2026, compared with 4.8 in 1H 2025, highlighting continued success in deepening patient engagement and expanding utilisation across the Group's broader diagnostic offering. Walk-in Segment (31% of Group revenue in 1H 2026) Within the walk-in segment, revenues reached EGP 1,501 million in 1H 2026, up 30% year-on-year compared with EGP 1,159 million in 1H 2025. Performance was driven by a 24% increase in test volumes alongside a 4% increase in average revenue per test, supported by continued patient traffic growth and rising utilisation of specialised diagnostics and radiology services. Average tests per patient within the walk-in segment improved to 4.0 tests in 1H 2026, compared with 3.8 in the prior-year period, reflecting the ongoing effectiveness of IDH's cross-selling initiatives, digital outreach programmes, and broader efforts to enhance the patient experience across its expanding network. Detailed Segment Performance Breakdown Walk-in Segment Contract Segment Total 1H 20251H 2026 Change 1H 20251H 2026 Change 1H 20251H 2026 Change Revenue (EGP mn) 1,159 1,501 30% 2,383 3,355 41% 3,543 4,856 37% Patients ('000) 840 994 18% 3,424 3,867 13% 4,265 4,861 14% % of patients 20% 20% 80% 80% Revenue per Patient (EGP) 1,380 1,510 9% 696 868 25% 831 999 20% Tests ('000) 3,178 3,943 24% 16,441 19,685 20% 19,619 23,629 20% % of Tests 16% 17% 84% 83% Revenue per Test (EGP) 365 381 4% 145 170 18% 181 206 14% Test per Patient 3.8 4.0 5% 4.8 5.1 6% 4.6 4.9 6% Revenue Analysis: Contribution by Geography Egypt (85.9% of Group revenue in 1H 2026) IDH's home and largest market, Egypt, continued to deliver strong growth during 1H 2026, with revenues increasing 41% year-on-year to EGP 4,170 million, compared with EGP 2,966 million in 1H 2025. Performance was supported by a 21% increase in tests performed alongside a 16% rise in average revenue per test, reflecting continued growth in patient volumes, pricing optimisation, and a progressively richer diagnostic mix. The Egyptian business also continued to benefit from IDH's expanding branch network, which reached 793 branches as at 30 June 2026, up 157 branches year-on-year. During the period, IDH served 4.6 million patients in Egypt, up 14% year-on-year, further underscoring the resilience of demand and the strength of the Group's brands in its home market. Al-Borg Scan and Radiotherapy IDH's radiology and radiotherapy platform, comprising Al Borg Scan and the radiotherapy offering added following the acquisition of Cairo Ray for Radiotherapy in June 2025, continued to increase its contribution to the Group's Egyptian operations during 1H 2026. Combined radiology and radiotherapy revenues reached EGP 220 million during the period, compared with EGP 123 million in 1H 2025, representing year-on-year growth of 79%. Growth was supported by both higher volumes and improved pricing, with total scans and radiotherapy procedures increasing 40% year-on-year to 162 thousand, while average revenue per test increased 28% year-on-year to EGP 1,358. During the period, the platform served 121 thousand patients, up 41% year-on-year, while the network expanded to nine branches, including eight Al Borg Scan branches and one radiotherapy facility. The continued expansion of IDH's radiology and radiotherapy platform strengthens the Group's positioning across higher- value specialised diagnostics and oncology-related services, while supporting its strategy to build a more comprehensive offering for patients and referring physicians. House Calls IDH's house-call service remained a core pillar of its Egyptian operations during 1H 2026, accounting for approximately 22% of Egypt's revenues, broadly in line with recent periods and significantly above pre-pandemic levels. The service continued to benefit from strong patient adoption, supported by enhanced digital booking capabilities, efficient logistics, and the Group's extensive nationwide network. Wayak Wayak, IDH's digital health and e-pharmacy platform, delivered revenues of EGP 21 million in 1H 2026, compared with EGP 15 million in 1H 2025, representing year-on-year growth of 38%. Performance was supported by continued optimisation of
Page 6
the platform's delivery network, growing integration with IDH's broader branch and digital ecosystem, and the Group's ongoing efforts to leverage its expanding patient database to provide personalised, digitally enabled healthcare services. Detailed Egypt Performance Breakdown 1H 2025 1H 2026 Change Revenue (EGP mn, contribution to Egypt's results) 2,966 4,170 41% Pathology Revenue 2,843 (95.9%)3,950 (94.7%) 39% Radiology & Radiotherapy Revenue 123 (4.1%)220 (5.3%) 79%Tests performed (mn) 18.0 21.8 21%Revenue per test (EGP) 164 191 16% Jordan (11.1% of Group revenue in 1H 2026) In IDH's second-largest market, Jordan, Biolab reported revenues of JOD 7.5 million in 1H 2026, representing an 8% year-on- year increase compared with JOD 7.0 million in 1H 2025. Growth was primarily volume-led, with the number of tests performed increasing 10% year-on-year, supported by higher tests per patient and the continued effectiveness of promotional, cross-selling, and loyalty initiatives implemented across the network. Patients served remained broadly stable during the period, increasing 1% year-on-year, while average tests per patient rose to 8.4 from 7.7 in 1H 2025. Average revenue per test in EGP terms declined slightly by 1% year-on-year, reflecting pricing dynamics within Jordan's regulated healthcare market and the Group's ongoing strategy to support patient retention and market share growth in a competitive environment. In Egyptian pound terms, revenues increased 9% year-on-year to EGP 537 million. Detailed Jordan Performance Breakdown 1H 2025 1H 2026 Change Revenue (EGP mn) 493 537 9%Revenue (JOD mn) 7.0 7.5 8%Tests performed (000s) 1,401 1,544 10%Revenue per test (EGP) 352 348 -1% Nigeria (1.5% of Group revenue in 1H 2026) Echo-Lab, IDH's Nigerian subsidiary, reported revenues of NGN 2.0 billion in 1H 2026, representing 12% year-on-year growth compared with NGN 1.8 billion in 1H 2025. Revenue growth was supported by continued pricing adjustments implemented to offset local inflationary pressures, with average revenue per test increasing 23% year-on-year in EGP terms, alongside a 3% increase in test volumes. Patient volumes remained broadly stable during the period, while tests per patient improved slightly to 2.2 from 2.1 in 1H 2025, reflecting continued operational progress across the business. In Egyptian pound terms, revenues rose 27% year-on- year to EGP 73 million, supported by both underlying operational growth and FX translation effects. Saudi Arabia (1.5% of Group revenue in 1H 2026) Biolab KSA, IDH's Saudi Arabian venture, recorded revenues of SAR 5.5 million in 1H 2026, representing 191% year-on-year growth compared with SAR 1.9 million in 1H 2025. In Egyptian pound terms, revenues increased 199% year-on-year to EGP 76 million, reflecting the continued ramp-up in operations and growing brand recognition across the Kingdom. Growth was supported by a sharp increase in patient and test volumes as the network expanded to five operational branches. During the period, patients served increased 144% year-on-year, while tests performed rose 194%, highlighting continued momentum in patient acquisition and utilisation across the platform. Over the coming period, IDH plans to continue expanding its footprint in the Kingdom in a disciplined and value-accretive manner. Sudan In Sudan, operations remained severely constrained by the ongoing conflict. One branch remained partially operational throughout the quarter, while the remaining 17 branches continued to be closed indefinitely pending stabilisation of conditions in the country. Management continues to closely monitor developments on the ground while prioritising the safety of employees and patients. Revenue Contribution by Country 1H 2025 1H 2026 Change Egypt Revenue (EGP mn) 2,966 4,170 41%Pathology Revenue (EGP mn) 2,843 3,950 39%Radiology Revenue (EGP mn) 123 193 57%Radiotherapy Revenue (EGP mn) 0 27 -Egypt Contribution to IDH Revenue 83.7% 85.9% Jordan Revenue (EGP mn) 493 537 9%Jordan Revenues (JOD mn) 7.0 7.5 8%Jordan Revenue Contribution to IDH Revenue 13.9% 11.1% Nigeria Revenue (EGP mn) 58 73 27%Nigeria Revenue (NGN mn) 1,768 1,986 12%Nigeria Contribution to IDH Revenue 1.6% 1.5% Saudi Arabia Revenue (EGP mn) 25 76 199%Saudi Arabia Revenue (SAR mn) 1.9 5.5 190%Saudi Arabia Contribution to IDH Revenue 0.7% 1.6% Average Exchange Rate 1H 2025 1H 2026 Change USD/EGP 50.20 50.71 1%
Page 7
JOD/EGP 70.71 71.40 1%NGN/EGP 0.03 0.04 13%SAR/EGP 13.40 13.51 0.8%SDG/EGP 0.01 0.01 - Patients Served and Tests Performed by Country 1H 2025 1H 2026 Change Egypt Patients Served (mn) 4.0 4.6 14%Egypt Tests Performed (mn) 18.0 21.8 21%Jordan Patients Served (k) 181 183 1%Jordan Tests Performed (k) 1,401 1,544 10%Nigeria Patients Served (k) 55 55 0%Nigeria Tests Performed (k) 116 120 3%Saudi Arabia Patients Served (k) 11 28 144%Saudi Arabia Tests Performed (k) 57 167 194%Total Patients Served (mn) 4.3 4.9 14%Total Tests Performed (mn) 19.6 23.6 20% Operational Branches by Country 30 June 2025 30 June 2026 Change Egypt 636 793 +157Jordan 27 29 +2Nigeria 12 11 -1KSA 2 5 +3Sudan 1 1 -Total 678 839 +161 Cost of Goods Sold (COGS) IDH's cost of goods sold amounted to EGP 2,751 million in 1H 2026, marking a 34% increase year-on-year, in line with higher activity levels, continued branch expansion, and ongoing investment in operational capacity across the Group's footprint. As a proportion of consolidated revenue, COGS improved to 56.7% in 1H 2026, compared with 58.0% in 1H 2025. The improvement reflects continued procurement optimisation, disciplined cost management, and scale efficiencies across IDH's operations. This was particularly evident in the Group's raw materials and specialised analysis cost base, as well as direct depreciation and amortisation, both of which declined as a percentage of revenue during the period. COGS Breakdown as a Percentage of Revenue 1H 2025 1H 2026 Raw Materials 19.6% 18.1%Wages & Salaries 19.1% 19.1%Depreciation & Amortisation 7.0% 6.2%Other Expenses 12.3% 13.3%Total 58.0% 56.7% Raw materials including the cost of specialised analysis at other laboratories, stood at EGP 880 million in 1H 2026, comparedwith EGP 693 million in 1H 2025. As a percentage of revenue, raw materials and specialised analysis costs improved to 18.1%from 19.6% in the prior-year period, reflecting continued procurement optimisation, improved inventory planning, andstronger supplier negotiations, which helped partially offset inflationary pressures and support higher testing volumes. Direct wages and salaries, including employee profit-sharing, amounted to EGP 925 million in 1H 2026, compared with EGP676 million in 1H 2025. As a percentage of revenue, direct wages and salaries remained broadly stable at 19.1% in bothperiods, reflecting the Group's ability to support continued branch expansion and higher activity levels while maintainingoperating efficiency. Direct Wages and Salaries by Region 1H 2025 1H 2026 ChangeEgypt (EGP mn) 515 738 43%Jordan (EGP mn) 134 148 10%Jordan (JOD mn) 1.9 2.0 5%Nigeria (EGP mn) 13 18 47%Nigeria (NGN mn) 385 501 30%Saudi Arabia (EGP mn) 13 20 52%Saudi Arabia (SAR k) 1,004 1,510 50% Direct depreciation and amortisation recorded EGP 299 million in 1H 2026, compared with EGP 249 million in 1H 2025.Despite continued investment in branch openings, radiology expansion, and diagnostic equipment across the network,depreciation and amortisation declined to 6.2% of revenue from 7.0% in the prior-year period, supported by strongerrevenue generation and improved cost absorption. Other direct costs, including hospital contracts, maintenance, utilities, transport, consulting, and licensing expenses, reached EGP 646 million in 1H 2026, compared with EGP 436 million in 1H 2025. As a percentage of revenue, other direct costs increased to 13.3% from 12.3%, reflecting higher activity levels, branch network expansion, and increased operational support costs across the Group's growing platform. Gross Profit IDH generated gross profit of EGP 2,105 million in 1H 2026, representing a 41% year-on-year increase compared with EGP 1,489 million in 1H 2025. Gross profit margin improved to 43.3%, compared with 42.0% in the prior-year period, reflecting the continued resilience of the Group's operating model and its ability to capture operating leverage as volumes expanded across the platform.
Page 8
Margin performance during the period was supported by strong revenue growth, continued procurement optimisation, improved inventory planning, and stronger cost absorption across the Group's expanding network. Raw materials and specialised analysis costs improved to 18.1% of revenue from 19.6% in 1H 2025, while direct depreciation and amortisation also declined as a percentage of revenue, supported by stronger activity levels and improved utilisation. Selling, General, and Administrative (SG&A) Expenses IDH's SG&A expenses amounted to EGP 780 million in 1H 2026, representing a 37% increase year-on-year compared with EGP 568 million in 1H 2025. As a percentage of consolidated revenue, SG&A remained broadly stable at 16.1% in 1H 2026, compared with 16.0% in the prior-year period. The year-on-year movement in SG&A was primarily driven by the following factors: · Indirect wages and salaries reached EGP 312 million in 1H 2026, up 18% year-on-year from EGP 263 million in 1H2025, reflecting annual salary adjustments, selective headcount additions to support branch expansion and newerbusiness lines, as well as FX translation effects on Jordanian and Saudi payroll costs.· Advertising and marketing expenses increased 56% year-on-year to EGP 151 million, as IDH continued investing inbrand visibility, patient acquisition campaigns, and promotional initiatives, particularly in Saudi Arabia in support ofthe ongoing ramp-up of Biolab KSA, alongside continued marketing efforts across Egypt and Jordan. Selling, General, and Administrative Expenses EGP mn 1H 2025 1H 2026 Change Wages & Salaries 263 312 18%Accounting and Professional Fees 84 110 31%Market - Advertisement expenses 97 151 56%Other Expenses - Operation 96 146 52%Depreciation & Amortisation 20 23 15%Impairment Loss on Trade and Other Receivable 18 22 22%Travelling and Transportation Expenses 16 19 19%Other Income -25 -2 -92%Total 568 780 37% EBITDA IDH reported EBITDA of EGP 1,647 million in 1H 2026, representing a 38% year-on-year increase compared with EGP 1,190 million in 1H 2025. EBITDA margin recorded 33.9%, broadly in line with the 33.6% recorded in the prior-year period. The Group's EBITDA performance was supported by strong top-line growth, improved gross profitability, procurement optimisation, and continued operating leverage across the platform, while ongoing investment in growth initiatives, particularly in Saudi Arabia and the expansion of the Group's radiology and radiotherapy platform, continued to support long-term growth. On a quarterly basis, IDH reported EBITDA of EGP 1,036 million in Q2 2026, up 50% year-on-year from EGP 691 million in Q2 2025. EBITDA margin expanded to 37.2% in Q2 2026, compared with 35.3% in the prior-year quarter, reflecting stronger revenue growth, improved cost absorption, and a more normalised operating environment following the seasonal impact of Ramadan and Eid in Q1 2026. EBITDA by Country In Egypt, IDH generated EBITDA of EGP 1,519 million in 1H 2026, up 42% year-on-year from EGP 1,072 million in 1H 2025. EBITDA margin recorded 36.4%, broadly in line with the 36.1% recorded in the prior-year period, reflecting strong revenue growth, continued cost discipline, and operating leverage across the Group's largest market. In Jordan, Biolab reported EBITDA of JOD 2.0 million in 1H 2026, broadly stable compared with 1H 2025. EBITDA margin recorded 26%, compared with 29% in the prior-year period, reflecting the impact of promotional pricing initiatives and continued investment in patient acquisition and loyalty programmes aimed at supporting long-term volume growth and market positioning. In Nigeria, Echo-Lab continued to build on its operational turnaround, reporting EBITDA of NGN 142 million in 1H 2026, compared with NGN 40 million in 1H 2025. EBITDA margin improved to 7%, versus 2% in the prior-year period, supported by pricing adjustments, improved operating leverage, and continued cost rationalisation efforts. In Saudi Arabia, Biolab KSA recorded EBITDA losses of SAR 1.2 million in 1H 2026, compared with losses of SAR 1.9 million in 1H 2025. EBITDA margin improved significantly to negative 21%, compared with negative 101% in the prior-year period, reflecting the continued ramp-up in revenues, stronger utilisation of fixed costs, and early-stage operating leverage as the business scales its operations across the Kingdom. Regional EBITDA in Local Currency 1H 2025 1H 2026 Change Egypt EBITDA (EGP mn) 1,072 1,519 42%Margin 36.1% 36.4% 0.3 pts.Jordan EBITDA (JOD k) 2,030 1,960 -3%Margin 29.0% 26.0% 3.0 pts.Nigeria EBITDA (NGN mn) 40.0 141.8 254%Margin 2.0% 7.0% 5.0 pts.Saudi Arabia EBITDA (SAR mn) (1.9) (1.2) -36%Margin (101%) (21%) 80.0 pts. Interest Income / Expense
Page 9
IDH recorded interest income of EGP 110 million in 1H 2026, compared with EGP 107 million in 1H 2025, representing a 2% year-on-year increase. The improvement reflects the Group's continued healthy liquidity position and treasury income generation during the period. Total interest expense5 increased to EGP 150 million in 1H 2026, compared with EGP 97 million in 1H 2025, representing a 55% year-on-year increase. The increase was primarily attributable to: · Interest on leases rising to EGP 80 million in 1H 2026, up 29% year-on-year, reflecting the continued expansion of the Group's branch network and the associated lease liabilities under IFRS 16. · Interest expense on financial obligations increasing to EGP 15 million, compared with EGP 13 million in 1H 2025, broadly in line with the Group's existing lease and financing obligations. · Interest expense on borrowings increasing significantly to EGP 40 million, compared with EGP 11 million in 1H 2025, primarily due to higher average debt balances following the loan drawdown related to the Cairo Ray acquisition, alongside elevated financing costs during the period. · Bank charges increasing to EGP 15 million in 1H 2026, compared with EGP 11 million in the prior-year period, in line with higher transaction volumes and continued business growth across the Group. It is important to note that IDH's interest-bearing debt6 interest-bearing debt stood at EGP 378 million as at 30 June 2026, compared with EGP 432 million at year-end 2025. The decrease primarily reflects the repayment of short-term borrowings during the period, partially offset by accrued interest and the Group's outstanding long-term borrowing balance. Interest Expense Breakdown EGP mn 1H 2025 1H 2026 Change Interest on Leases 62 80 29%Interest Expenses on Financial Obligations 13 15 18%Interest Expenses on Borrowings 11 40 278%Bank Charges 11 15 31%Total Interest Expense 97 150 55% 5 Interest expenses on medium-term loans include EGP 39 million in 1H 2026 (EGP 9 million in 1H 2025) related to the Group's facility with Kuwait Finance House (KFH) - formerly Ahli United Bank (AUB).6 IDH's interest-bearing debt as at 30 June 2026 included EGP 367 million (EGP 403 million as at 31 December 2025) related to its facility with Kuwait Finance House (KFH) - formerly Ahli United Bank (AUB) (outstanding loan balances are excluding accrued interest for the period). Foreign Exchange IDH recorded a foreign exchange gain of EGP 37 million in 1H 2026, compared with a foreign exchange loss of EGP 3 million in 1H 2025. The foreign exchange gain primarily relates to the revaluation of intercompany balances denominated in currencies different from the respective entities' functional currencies. Taxation Tax expenses, including current and deferred tax, amounted to EGP 483 million in 1H 2026, compared with EGP 342 million in 1H 2025. IDH's effective tax rate remained broadly stable year-on-year at 37% in 1H 2026, compared with 37% in the prior- year period. The Group's effective tax rate continues to reflect the geographic mix of taxable profits across its operating subsidiaries, as well as the impact of foreign exchange movements related to intercompany balances. It is important to highlight that there is no tax payable at the level of IDH's two holding companies. Taxation Breakdown by Region EGP mn 1H 2025 1H 2026 Change Egypt 330 470 43% Jordan 8.4 7.1 -15% Nigeria 0.2 0.4 112% KSA 3.8 5.0 31% Total Tax Expenses 342 483 41% Net Profit IDH recorded a net profit of EGP 839 million in 1H 2026, representing a 47% year-on-year increase from EGP 571 million in 1H 2025. Net profit margin expanded to 17.3% in 1H 2026, compared with 16.1% in the prior-year period. The strong bottom-line growth was supported by higher operating profitability, with operating profit increasing 44% year-on- year to EGP 1,325 million, alongside the foreign exchange gain recorded during the period, which primarily relates to the revaluation of foreign currency-denominated intercompany balances. Excluding foreign exchange gains/losses in both periods, adjusted net profit rose 40% year-on-year to EGP 802 million in 1H 2026, with the associated adjusted net profit margin improving to 16.5% compared with 16.2% in 1H 2025, highlighting the continued strength of the Group's underlying operating performance. On a quarterly basis, IDH recorded net profit of EGP 402 million in Q2 2026, up 23% year-on-year from EGP 326 million in Q22025, despite higher foreign exchange losses recorded during the quarter. Excluding foreign exchange losses in both periods,adjusted net profit increased 42% year-on-year to EGP 510 million in Q2 2026. ii. Balance Sheet Analysis
Page 10
Assets Property, Plant and Equipment (PPE) IDH recorded PPE cost of EGP 4,348 million as at 30 June 2026, up from EGP 3,900 million at year-end 2025. The increase primarily reflects the addition of new branches across key markets, continued investments in laboratory and radiology equipment, and the renovation and upgrade of existing locations to enhance service quality and operational capacity. Total CAPEX Addition Breakdown - 1H 2026 EGP mn 1H 2026 % of Revenue Leasehold Improvements/new branches 369 8% Radiotherapy (Cairo Ray acquisition) 2 0.03%Al-Borg Scan Expansion 50 1%CAPEX Additions 422 9%Translation Effect 38 1% Disposals (11) -0.2%Total Increase in PPE Cost 448 9% Trade Receivables and Provisions Net trade receivables stood at EGP 1,381 million as at 30 June 2026, compared with EGP 996 million at year-end 2025. Days on Hand (DOH) stood at 131 days, compared with 122 days at the end of 2025. Meanwhile, provision charges for doubtful accounts in 1H 2026 stood at EGP 22 million, compared with EGP 18 million in 1H 2025. Inventory As at 30 June 2026, IDH's inventory balance stood at EGP 686 million, compared with EGP 424 million at year-end 2025. Meanwhile, Days Inventory Outstanding (DIO) stood at 119 days, versus 94 days at 31 December 2025. The increase reflects a deliberate inventory build-up strategy implemented by management to secure the availability of critical medical supplies and test kits amid heightened regional tensions and ongoing uncertainty surrounding global supply chains and logistics routes. Cash and Net Debt Cash balances and financial assets at amortised cost reached EGP 1,926 million as at 30 June 2026, compared with EGP 2,090 million at year-end 2025. The balance includes cash on hand and at banks of EGP 1,653 million and other investments of EGP 273 million. EGP mn 31 December 2025 30 June 2026 Treasury Bills 1,604 505 Time Deposits 123 290Current Accounts 326 1,099Cash on Hand 37 33Total 2,090 1,926 IDH's net cash7 balance recorded EGP 239 million as at 30 June 2026, compared to a net cash balance of EGP 472 million at year-end 2025. EGP mn 31 December 2025 30 June 2026 Cash and Financial Assets at Amortised Cost8 2,090 1,926 Lease Liabilities Property* (1,006) (1,039) Total Financial Liabilities (Short-term and Long-term) (180) (270) Interest-Bearing Debt ("Medium Term Loans")** (432) (378) Net Cash/(Debt) Balance 472 239 Note: Interest Bearing Debt includes accrued interest for each period.*If excluding Lease Liabilities Property (IFRS 16), IDH would have recorded net cash of EGP 1,278 million.**Includes accrued finance cost. Lease liabilities and financial obligations related to property stood at EGP 1,039 million as at 30 June 2026, compared withEGP 1,006 million at year-end 2025, reflecting the continued expansion of the Group's branch network and associated leaseliabilities under IFRS 16. Meanwhile, total financial liabilities, including short- and long-term obligations related primarily to equipment financing,recorded EGP 270 million as at 30 June 2026, compared with EGP 180 million at 31 December 2025. Finally, interest bearing debt9 (including accrued interest) stood at EGP 378 million as at 30 June 2026, compared with EGP432 million at year-end 2025. Liabilities Trade Payable10 As at 30 June 2026, IDH's trade payables stood at EGP 647 million, up from EGP 563 million at year-end 2025. Meanwhile,Days Payable Outstanding (DPO) recorded 130 days, compared with 112 days at 31 December 2025. Put OptionThe put option current liability stood at EGP 651 million as at 30 June 2026, compared with EGP 629 million at 31 December2025, and is related to both:· The option granted in 2011 to Dr. Amid, Biolab's CEO, to sell his stake (40%) to IDH. The put option is in the moneyand exercisable since 2016 and is calculated as seven times Biolab's LTM EBITDA minus net debt.· The option granted in 2018 to the International Finance Corporation from Dynasty - shareholders in Echo Lab - andit is exercisable in 2024. The put option is calculated based on fair market value (FMV).
Page 11
It is important to note that the put option previously included as part of the agreement between IDH, Biolab and Izhoor inSaudi Arabia has been removed following IDH's acquisition of Izhoor's entire 49% stake in Biolab KSA, which was concluded inDecember 2024. Biolab KSA is now owned 79% by IDH and 21% by its Jordanian subsidiary Biolab. 7 The net cash/(debt) balance is calculated as cash and cash equivalent balances including financial assets at amortised cost, less interest-bearing debt (medium term loans), finance lease and right-of-use liabilities. 8 It is worth noting that some term deposits and treasury bills cannot be accessed for over three months and are therefore not treated as cash. Term deposits which cannot be accessed for over three months stood at EGP 39 million at 30 June 2026 (31 December 2025: EGP 336 million). Meanwhile, treasury bills not accessible for over three months stood at EGP 235 million (31 December 2025: EGP 83 million). 9 IDH's interest-bearing debt as at 30 June 2026 included EGP 367 million to its facility with Kuwait Finance House (KFH) - formerly Ahli United Bank (AUB) (outstanding loan balances are excluding accrued interest for the period). 10 Accounts payable is calculated based on average payables at the end of each period. Subsequent Event: Shareholder Update Hena Holdings Ltd, IDH's founding shareholder vehicle, which is wholly owned by IDH Chief Executive Officer Dr. Hend El-Sherbiniand her mother, Dr. Moamena Abdul Wahab Kamel, increased its shareholding in the Company during the period through amandatory cash offer. On 23 June 2026, Hena Holdings announced the offer following its acquisition of 126 million shares from Actis IDH Limited,representing 21.67% of IDH's total voting rights. The acquisition increased Hena Holdings' total ownership to 49.62%, triggering amandatory takeover offer under the UK Takeover Code. The initial offer period closed on 29 July 2026, followed by a final two-week extension, which expired on 12 August 2026. Following completion of the offer process and final settlements, HenaHoldings acquired additional shares through the offer, bringing its total ownership in IDH to 56.67%. Principal Risks and Uncertainties As in any corporation, IDH has exposure to risks and uncertainties that may adversely affect its performance. The Board andsenior management agree that the principal risks and uncertainties facing the Group include political and economic risks in Egypt,the Middle East and Nigeria, foreign currency exchange rate variability and associated risks, changes in regulation and regulatoryactions, damage to the Group's reputation, failure to maintain the Group's high quality standards and accreditations, failure tomaintain good relationships with healthcare professionals and end users, pricing pressures and business interruption of theGroup's testing facilities, among others. In the short term, other factors influencing the economic landscape include rising geopolitical instability, inflationary pressures inEgypt and Nigeria, and currency devaluation in both countries. These factors may weigh on the cost base in the near future. Statement of Directors' Responsibilities Responsibility statement of the directors in respect of the half-yearly financial report We confirm that to the best of our knowledge, the interim management report includes a fair review of the information required by: (a) DTR 4.2.7R of the Disclosure Guidance and Transparency Rules, being an indication of important events that have occurredduring the first six months of the financial year and their impact on the condensed set of financial statements; and a descriptionof the principal risks and uncertainties for the remaining six months of the year; and (b) DTR 4.2.8R of the Disclosure Guidance and Transparency Rules, being related party transactions that have taken place in thefirst six months of the current financial year and that have materially affected the financial position or performance of the entityduring that period; and any changes in the related party transactions described in the last annual report that could do so. For and on behalf of the Board of Directors Dr. Hend El Sherbini Executive Director11 September 2026
Page 12
INTEGRATED DIAGNOSTICS HOLDINGS plc - "IDH"AND ITS SUBSIDIARIES Condensed Consolidated InterimFinancial Information for the six months period ended 30 June 2026 Consolidated statement of financial position as at 30 June 2026 30 June 2026 31 December 2025 EGP'000 EGP'000 Notes (Unaudited) (Audited) ASSETS Non-current assets Property, plant and equipment 4 2,216,948 1,992,972 Intangible assets and goodwill 5 1,857,705 1,852,521 Right of use assets 6 819,849 797,879 Total non-current assets 4,894,502 4,643,372 Current assets Inventories 685,972 424,428 Trade and other receivables 8 1,763,089 1,402,301 Financial assets at fair value through profit and loss 7 36,439 35,285 Financial assets at amortized cost 9 273,327 419,002 Cash and cash equivalents 10 1,652,748 1,670,799 Total current assets 4,411,575 3,951,815 Total assets 9,306,077 8,595,187 Equity and liabilities Equity Share Capital 1,039,121 1,039,121 Share premium reserve 1,027,706 1,027,706 Capital reserve (314,310) (314,310) Capital Redemption Reserve 33,379 33,379 Legal reserve 51,641 51,641 Put option reserve 12 (651,314) (628,645) Translation reserve (460,006) (446,198) Future Minority Interest Reserve 23,813 23,813 Retained earnings 3,175,148 2,596,607
Page 13
Equity attributable to the equity holders of the parent 3,925,178 3,383,114 Non-controlling interests 786,160 747,262 Total equity 4,711,338 4,130,376 Non-current liabilities Provisions 19,233 14,051 Borrowings 13 253,493 253,493 Other financial obligations 14 1,025,037 941,037 Deferred tax liabilities 19-B 651,127 558,654 Total non-current liabilities 1,948,890 1,767,235 Current liabilities Trade and other payables 11 1,213,265 1,121,523 Other financial obligations 14 284,048 244,857 Current put option liability 12 651,314 628,645 Borrowings 13 121,619 173,849 Current tax liabilities 375,603 528,702 Total current liabilities 2,645,849 2,697,576 Total liabilities 4,594,739 4,464,811 Total equity and liabilities 9,306,077 8,595,187 These condensed consolidated interim financial information were approved and authorized for issue by the Board of Directors and signedon their behalf on 10 September 2026 by: ____________________ ________________________________Dr. Hend El Sherbini Sherif El Zeiny Chief Executive Officer Chief Financial Officer The accompanying notes form an integral part of these condensed consolidated interim financial information. Consolidated income statement for the six months ended 30 June 2026 For the six-month period ended 30 June 2026 2025 Notes EGP'000 EGP'000 (Unaudited) (Unaudited) Revenue 22 4,856,406 3,542,688 Cost of sales (2,751,328) (2,053,405) Gross profit 2,105,078 1,489,283 Marketing and advertising expenses (307,783) (193,302) Administrative expenses 16 (453,034) (392,604) Impairment loss on trade and other receivable (21,577) (17,675) Other income 2,463 25,458 Operating profit 1,325,147 911,160 Net fair value losses on financial assets at fair value through profit 17 - (4,940) Finance costs 18 (149,982) (100,329) Finance income 18 146,562 107,363 Net finance (loss)/income (3,420) 7,034 Profit for the period before tax 1,321,727 913,254
Page 14
Income tax expense 19-A (482,581) (341,960) Net profit for the period 839,146 571,294 Profit attributed to: Owners of the Company 821,535 551,354 Non-controlling interests 17,611 19,940 839,146 571,294 Earnings per share (expressed in EGP): Basic and diluted earnings per share 21 1.41 0.95 The accompanying notes form an integral part of these condensed consolidated interim financial information. Consolidated statement of comprehensive income for the six months ended 30 June 2026 For the six-month period ended 30 June 2026 2025 EGP'000 EGP'000 (Unaudited) (Unaudited) Profit for the period 839,146 571,294 Items that may be reclassified to profit or loss: Exchange difference on translation of foreign operations 7,479 (40,365) Other comprehensive income/(loss) for the period net of tax 7,479 (40,365) Total comprehensive income for the period 846,625 530,929 Attributed to: Owners of the Company 807,727 613,810 Non-controlling interests 38,898 (82,881) 846,625 530,929 The accompanying notes form an integral part of these condensed consolidated interim financial information. Consolidated statement of cash flows for the six months ended 30 June 2026 30-Jun 2026 30-Jun 2025 EGP'000 EGP'000 Note (Unaudited) (Unaudited) Cash flows from operating activitiesProfit for the period before tax 1,321,727 913,254Adjustments Depreciation of property, plant and equipment 4 201,530 160,198Depreciation of right of use assets 6 107,598 97,755Amortisation of intangible assets 5 13,007 10,567Interest income 18 (109,671) (107,363)Interest expense 18 135,150 85,543Bank Charges 14,832 11,293Loss/(gain) on disposal of PPE 398 (1,951)Impairment in trade and other receivables 21,577 17,675ROU Asset/Lease Termination (964) 3,928Unrealised foreign currency exchange (gains) losses (36,891) 3,494FV Through P&L - 4,940Change in Provisions 5,179 1,843Change in Inventories (259,407) (53,405)
Page 15
Change in trade and other receivables (350,672) (363,436) Change in trade and other payables 118,351 (27,117) Cash generated from operating activities before income taxpayment 1,181,745 757,218 Tax paid during period (547,029) (363,171) Net cash generated from operating activities 634,716 394,046 Cash flows from investing activities Interest received on financial asset at amortised cost 124,907 115,067Payments for the purchase of financial assets at amortized cost (247,275) (353,849)Proceeds for the sale of financial assets at amortized cost 402,951 467,317Payments for acquisition of property, plant and equipment 4 (281,627) (112,806)Payments for acquisition of intangible assets 5 (11,466) (82,223)Proceeds from sale of Property, plant and equipment 8,918 3,261Payment for purchase of global depository receipts (short-terminvestment) 17 - (55,047)Proceeds from sale of global depository receipts (short-terminvestments) 17 - 50,107 Net cash (used in)/generated from investing activities (3,592) 31,828 Cash flows from financing activities Proceeds from borrowings - 104,962Repayments of borrowings (56,409) (191,035)Interest paid (136,332) (87,402)Bank charges paid (14,832) (11,293)Payment of finance lease liabilities (152,716) (113,509)Dividends paid (242,994) (2,478) Net cash flows used in financing activities (603,283) (300,755) Net decrease in cash and cash equivalent 27,841 125,120Cash and cash equivalents at the beginning of the period 1,670,799 1,188,082Effect of exchange rate (45,892) (13,947) Cash and cash equivalent at the end of the period 10 1,652,748 1,299,255 Non-cash investing and financing activities disclosed in other notes are· Property plant and equipment - note 4· Acquisition of right-of-use assets - note 6· Put option liability - note 12 The accompanying notes form an integral part of these condensed consolidated interim financial information. Consolidated statement of changes in equity for the sixmonths ended 30 June 2026 Attributable to owners of the Parent Sharecapital Sharepremiumreserve Capitalreserve Legalreserve* CapitalRedemptionReserve Putoptionreserve Translationreserve FutureMinorityInterestReserve Retainedearningst EGP'000 EGP'000 EGP'000EGP'000 EGP'000 EGP'000 EGP'000 EGP'000 EGP'000 Balance at 1 January 2026 1,039,1211,027,706(314,310)51,641 33,379 (628,645)(446,198)23,813 2,596,607 Profit for the period - - - - - - - - 821,535 Other comprehensive income forthe period - - - - - - (13,808) - - Total comprehensive income at30 June 2026 - - - - - - (13,808) - 821,535 Transactions with owners of theCompany Contributions and distributions Movement in put option liabilities - - - - - (22,669) - - - Dividends - - - - - - - - (242,994)
Page 16
Total contributions anddistributions - - - - - (22,669) - - (242,994) Balance at 30 June 2026(Unaudited) 1,039,1211,027,706(314,310)51,641 33,379 (651,314)(460,006)23,813 3,175,148 Balance at 1 January 2025 1,039,1211,027,706(314,310)51,641 33,379 (532,499)(407,595) - 1,812,706 Profit for the period - - - - - - - - 551,354 Other comprehensive profit/( loss)for the period - - - - - - 62,456 - - Total comprehensive income at30 June 2025 - - - - - - 62,456 - 551,354 Transactions with owners of theCompany Contributions and distributions Movement in put option liabilities - - - - - (200,281) - - - Dividends - - - - - - - - - Total contributions anddistributions - - - - - (200,281) - - - Balance at 30 June 2025(Unaudited) 1,039,1211,027,706(314,310)51,641 33,379 (732,780)(345,139) - 2,364,060 *Under Egyptian Law, each subsidiary in Egypt must set aside at least 5% of its annual net profit into a legal reserve until such time that this represents 50% of eadistributable to the owners of the Company.The accompanying notes on pages 24 - 39 form an integral part of these condensed consolidated interim financial information. Notes to the Condensed Consolidated Interim Financial InformationFor the six months period ended 30 June 2026 1. Reporting entity Integrated Diagnostics Holdings plc "IDH" or "the Company" is a Company which was incorporated in Jersey on 4 December 2014and established according to the provisions of the Companies (Jersey) Law 1991 under Registered No. 117257. These condensedconsolidated interim financial information as of and for the six months ended 30 June 2026 comprise the Company and itssubsidiaries (together referred as the 'Group'). The Company is a listed entity, in London Stock Exchange (since 2015). The principal activities of the Company and its subsidiaries (together "The Group") include investments in all types of thehealthcare field of medical diagnostics (the key activities are pathology and Radiology related tests) and radiotherapy, eitherthrough acquisitions of related business in different jurisdictions or through expanding the acquired investments they have. Thekey jurisdictions that the Group operates are in Egypt, Jordan, Nigeria, Sudan and Saudi Arabia. The Group's financial year starts on 1 January and ends on 31 December of each year. This condensed consolidated interim financial information was approved for issue by the Directors of the Company on 10September 2026. 2. Basis of preparation A) Statement of compliance This condensed consolidated interim financial information has been prepared as per IAS 34 'Interim Financial Reporting' (Asadopted by the IASB). as the accounting policies adopted are consistent with those of the previous financial year ended 31December 2025 and corresponding interim reporting period. These condensed consolidated interim financial information do not include all the information and disclosures in the annualconsolidated financial Statement, and should be read in conjunction with the financial Statement published as at and for the yearended 31 December 2025 which is available at www.idhcorp.com,. In addition, results of the six-month period ended 30 June2026 are not necessary indicative for the results that may be expected for the financial year ending 31 December 2026. B) Basis of measurement The condensed consolidated interim financial information has been prepared on the historical cost basis except where adoptedIFRS mandates that fair value accounting is required which is related to the financial assets and liabilities measured at fair value.
Page 17
C) Functional and presentation currency This condensed consolidated interim financial information is presented in Egyptian Pounds (EGP'000). The functional currency ofthe majority of the Group's entities is the Egyptian Pound (EGP) and is the currency of the primary economic environment inwhich the Group operates. The Group also operates in Jordan, Sudan, Nigeria and Saudi Arabia and the functional currencies of those foreign operations arethe local currencies of those respective territories, however due to the size of these operations, there is no significant impact onthe functional currency of the Group, which is the Egyptian Pound (EGP). 3. Significant accounting policies In preparing these condensed consolidated interim financial information, the significant judgments made by the management inapplying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that were appliedto the consolidated financial statements for the year ended 31 December 2025."The preparation of these condensedconsolidated interim financial information requires management to make judgements, estimates and assumptions that affect theapplication of accounting policies and the reported amounts of assets, liabilities, income and expense. Actual results may differfrom these estimates. Information about significant areas of estimation uncertainty and critical judgement in applying accountingpolicies that have the most significant effect on the amount recognised in the condensed consolidated interim financialstatement is described in note 3.2 of the annual consolidated financial statements published for the year ended 31 December2025. In preparing this condensed consolidated interim financial information, the significant judgments made by themanagement in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as thosethat were applied to the consolidated financial statements for the year ended 31 December 2025". 4. Property, plant and equipment Land &buildings Medical, &electricequipment Leaseholdimprovements Fixtures,fittings &vehicles Building &Leaseholdimprovements inconstruction Cost Balance at 1 January 2026 747,526 1,949,972 922,157 224,072 49,106 Additions 22 329,429 15,027 20,642 56,454Disposals - (10,138) (386) (842) -Exchange differences 3,023 17,485 12,098 4,740 631 Transfers - - 23,192 - (23,192) Balance at 30 June 2026 750,571 2,286,748 972,088 248,612 82,999 Depreciation Balance at 1 January 2026 91,529 1,053,269 630,583 131,869 - Depreciation for the period 7,215 120,513 61,778 12,024 -Disposals - (1,174) (367) (509) - Exchange differences 323 13,168 7,696 3,542 - Balance at 30 June 2026 99,067 1,185,776 699,690 146,926 - Net book amount At 30 June 2026 (Unaudited) 651,504 1,100,972 272,398 101,686 82,999 At 31 December 2025 655,997 896,703 291,574 92,203 49,106
Page 18
5. Intangible assets and goodwill Intangible assets represent goodwill acquired through business combinations and brand names. Goodwill Brand name Software TotalCost Balance at 1 January 2026 1,353,795 425,009 211,369 1,990,173Additions - - 11,466 11,466Exchange differences 5,198 2,005 1,037 8,240 Balance at 30 June 2026 1,358,993 427,014 223,872 2,009,879 Amortisation Balance at 1 January 2026 17,093 343 120,216 137,652Amortisation - - 13,007 13,007Exchange differences 609 1 905 1,515Balance at 30 June 2026 17,702 344 134,128 152,174 Net book amount At 30 June 2026 (Unaudited) 1,341,291 426,670 89,744 1,857,705At 31 December 2025 1,336,702 424,666 91,153 1,852,521 Goodwill impairment reviews are undertaken annually or more frequently if events or changes in circumstances indicate apotential impairment. No indicators of impairment have been identified during the six months ended 30 June 2026. 6. Right-of-use assets 30 June 2026 31 December 2025 (Unaudited) (Audited) Balance at 1 January 797,879 753,298 Addition for the period / year 122,469 274,484 Depreciation charge for the period / year (107,598) (197,913) Terminated contracts (1,393) (10,164) Exchange differences 8,492 (21,826) 819,849 797,879 7. Financial asset at fair value through profit or loss 30 June 2026 31 December 2025 (Unaudited) (Audited) Current equity investments 36,439 35,285 36,439 35,285 * On August 17, 2017, Al Makhbariyoun Al Arab (seller) has signed IT purchase Agreement with JSC Mega Lab (Buyer) totransfer and install the Laboratory Information Management System (LIMS) for a purchase price amounted to USD 400,000,which will be in the form of 10% equity stake in JSC Mega Lab. In case the valuation of the project is less or more than USD4,000,000, the seller stake will be adjusted accordingly, in a way that the seller equity stake shall not fall below 5% of JSCMega Lab. - Ownership percentage in JSC Mega Lab at the transaction date on April 8, 2019, and as of June 30, 2026, was 8.25%. On April 8, 2019, Al Mokhabariyoun Al Arab (Biolab) signed a Shareholder Agreement with JSC Mega Lab and JSC GeorgiaHealthcare Group (CHG), which meant that BioLab had a put option, exercisable within 12 months immediately after theexpiration of five (5) year period from the signing date. This put option allowed BioLab's stake to be bought out by CHG at aprice of the equity value of BioLab Shares/total stake (being USD 400,000) plus 15% annual IRR (including preceding 5Financial years). This option was not subsequently exercised, and therefore lapsed on April 8 2025. From this date, theagreement stated that CHG have a call option to purchase Biolab's shares at a price equivalent to the equity value of Biolab'sstake (being USD 400,000) plus the higher of 20% annual IRR or 6X EV/EBITDA (of the financial year immediately precedingthe call option exercise date). 8. Trade and other receivables 30 June 2026 31 December 2025 (Unaudited) (Audited) Trade receivables - net 1,380,858 996,485 Prepayments 148,967 121,558 Due from related parties note (15) 6,671 5,968 Other receivables * 222,236 258,697 Accrued revenue 4,357 19,593
Page 19
1,763,089 1,402,301 The expected credit loss related to trade and other receivables was EGP 246,853 K (2025: EGP 251,988 K). Below shows themovements in the provision for impairment of trade and other receivables: 30 June 2026 31 December 2025 (Unaudited) (Audited) Balance at 1 January 251,988 208,476 Charge for the period 21,577 45,108 Utilised (15,342) - Exchange differences (11,370) (1,596) 246,853 251,988 9. Financial assets at amortised cost 30 June 2026 31 December 2025 (Unaudited) (Audited) Term deposits (more than 3 months) 38,676 335,754 Treasury bills (more than 3 months) 234,651 83,248 273,327 419,002 The maturity date of the treasury bills and Fixed-term deposits are between more than 3 months. Treasury bills are of EGP25.00%. Fixed-term deposits more than 3 months have average interest rates of EGP and JOD 10.67% and 3.75% respectively. 10. Cash and cash equivalents 30 June 2026 31 December 2025 (Unaudited) (Audited) Cash at banks and on hand 1,131,826 363,261 Treasury bills (less than 3 months) 55,094 39,670 Term deposits (less than 3 months) 465,828 1,267,868 1,652,748 1,670,799 Cash at banks earns interest at floating rates based on daily bank deposit rates. Short-term deposits and treasury bills are madefor varying periods of between one day and three months, depending on the immediate cash requirements of the Group, andearn interest at the respective weighted average rate. Of the above, short-term deposits relate to amounts held in Egypt with aweighted average rate of Nil (2025: 16.94%),Short-term deposits relate to amounts held in Dubai with a weighted average rate of3.47%,Short-term deposits relate to amounts held in the United Kingdoms with a weighted average rate of 3.54%, Short-termdeposits relate to amounts held in Jordan with a weighted average rate of 3.5% (2025: 4.65%) and short-term deposits relate toamounts held in Mauritius with a weighted average rate of 3.80% (2025: 4.07%) and Treasury bills are denominated in EGP andearn interest at a weighted average rate of 23.77% (2025: 26.68%) per annum. 11. Trade and other payables 30 June 2026 31 December 2025 (Unaudited) (Audited) Trade payables 646,615 563,450 Accrued expenses 301,983 269,519 Due to related parties note (15) 11,464 35,619 Other payables 117,541 104,405 Deferred revenue 132,600 144,286 Accrued finance cost 2,455 4,244 Shareholders' dividend 607 - 1,213,265 1,121,523 12. Put option liability 30 June 2026 31 December 2025(Unaudited) (Audited)Current put option - Al Makhbariyoun Al Arab 597,059 578,151Current put option - Eagle Eye-Echo scan 54,255 50,494651,314 628,645
Page 20
Put option - Biolab Jordan The accounting policy for put options after initial recognition is to recognise all changes in the carrying value of the put optionliability within equity. Through the historic acquisitions of Makhbariyoun Al Arab the Group entered into separate put option arrangements to purchasethe remaining equity interests from the vendors at of a subsequent date. At acquisition, a put option liability has been recognisedat the net present value of the exercise price of the option. The option is calculated at seven times EBITDA of the last 12 months minus Net Debt and its exercisable in whole starting the fifthanniversary of completion of the original purchase agreement, which fell due in June 2016. The vendor has not exercised thisright on 30 June 2026. It is important to note that the put option liability is treated as current as it could be exercised at any timeby the NCI. However, based on discussions and ongoing business relationships, there is no expectation that this will happen in thenext 18 months the option has no expiry date. Put option - Eagle Eye-Echo scan IFC has the option to put its shares according to definitive agreements signed on 15 January 2018 between Dynasty groupHoldings Limited and International Finance Corporation (IFC) related to the Eagle Eye-Echo Scan Limited transaction, IFC has theoption to put it shares to Dynasty group Holdings Limited in year 2024. The put option price will be calculated on the basis of thefair market value determined by an independent valuer. 13. Loans and borrowings Currency Nominal interestrate Maturity 30 June 2026 31 December2025 (Unaudited) (Audited) Kuwait Finance Bank (AUB -Previously) EGP CBE corridorrate*+1% 26 January 2027 26,986 40,479 Kuwait Finance Bank (AUB -Previously) EGP CBE corridorrate*+0.75% 31 May 2030 340,000 340,000 Kuwait Finance Bank (AUB -Previously) EGP Secured 5% 3 December 2026 - 22,902 Bank Al Etihad JOD Secured 11.75% September 2026 8,126 23,961 375,112 427,342 Amount held as: Current liability 121,619 173,849 Non-current liability 253,493 253,493 375,112 427,342 * As at 30 June 2026, corridor rate 20.00% (2025: 21.00%) 13. Loans and borrowings (continued) A) In July 2018, AL-Borg lab, one of IDH subsidiaries, was granted a medium term loan amounting to EGP 130.5m fromKuwait Finance Bank (AUB - Previously) to finance the investment cost related to the expansion into the radiologysegment. As at 30 June 2026, only EGP 124.9M had been drawn down from the total facility available, with EGP 97.9Mrepaid. The loan will be fully repaid by January 2027. The loan contains the following financial covenants which if breached will mean the loan is repayable on demand: 1. The financial leverage shall not exceed 0.7 throughout the period of the loan."Financial leverage": total bank debt divided by net equity. 2. The debt service ratios (DSR) shall not be less than 1.35 starting 2020"Debt service ratio": cash operating profit after tax plus depreciation for the financial year less annual maintenanceon machinery and equipment adding cash balance (cash and cash equivalent) divided by total financial payments. "Cash operating profit": Operating profit after tax, interest expense, depreciation and amortisation, is calculated asfollows: Net income after tax and unusual items adding Interest expense, Depreciation, Amortisation and provisionsexcluding tax related provisions less interest income and Investment income and gains from extraordinary items. "Financial payments": current portion of long-term debt including finance lease payments, interest expense andfees and dividends distributions. 3. The current ratios shall not be less than 1."Current ratios": Current assets divided current liabilities. AL- Borg company didn't breach any covenants for MTL agreements. On June 2025 the company signed medium-term loan with Kuwait Finance Bank amounting to EGP 400 Mfor the acquisition of Radiotherapy branch which will be repaid on 31 May 2030 The loan contains thefollowing financial covenants which if breached will mean the loan is repayable on demand:1- The financial leverage shall not exceed 1 throughout the period of the loan"Financial leverage": total bank debt divided by equity2- The debt service ratios (DSR) shall not be less than 1.00 starting 2025The Company has complied with all financial covenants. Non-compliance with these covenants may result inpenalties, restrictions, or other remedies as stipulated in the agreement.
Page 21
14. Other financial obligations Future minimum financial obligation payments under leases and sales purchase contracts, together with the present value of thenet minimum lease payments are, as follows: 30 June 2026 31 December 2025 (Unaudited) (Audited)*Financial liability - laboratory equipment 270,066 179,840*Lease liabilities - building 1,039,019 1,006,0541,309,085 1,185,894 *The financial obligation liabilities for the laboratory equipment and building are payable as follows: 30 June 2026 Minimumpayments Interest Principal (Unaudited) (Unaudited) (Unaudited)Less than one year 456,261 172,213 284,048Between one and five years 1,216,161 452,257 763,904More than five years 357,797 96,664 261,1332,030,219 721,134 1,309,085 31 December 2025 Minimum payments Interest Principal (Audited) (Audited) (Audited) Less than one year 405,831 160,974 244,857 Between one and five years 1,096,393 395,180 701,213 More than Five years 334,449 94,625 239,824 1,836,673 650,779 1,185,894 Amounts recognised in profit or loss: 30 June 2026 2025 (Unaudited) (Unaudited)Interest on lease liabilities 79,855 62,053Expenses related to short-term lease 5,584 4,366 15. Related party transactions The significant transactions with related parties, their nature, volumes and balances during the period ended 30 June 2026 are asfollows: 30 June 2026 Related Party Nature of transaction Nature ofrelationship Transactionamount of theperiod Amount duefrom / (to) EGP'000 EGP'000 ALborg Scan (S.A.E)* Expenses paid on behalf Affiliate 17 17 International Fertility (IVF)** Expenses paid on behalf Affiliate 17 32 H.C Security Provide service Entity owned byCompany's boardmember (33) (123) Life Health Care Provided service Entity owned byCompany's CEO 494 1,913 Dr. Amid Abd Elnour Put option liability Bio. Lab C.E.O andshareholder (18,908) (597,059) Current account Bio. Lab C.E.O andshareholder 24,353 (5,821) Share based payment Bio. Lab C.E.O andshareholder (165) (5,520) International Financecorporation (IFC) Put option liability Echo-Scanshareholder (3,761) (54,255) Integrated Treatment forKidney Diseases (S.A.E) Rental income Entity owned byCompany's CEO (500) 4,709 Medical test analysis 675 (656,107)
Page 22
15. Related party transactions (continued) 31 December 2025 Related Party Nature oftransaction Nature ofrelationship Transactionamount of theyear Amountdue from /(to) EGP'000 EGP'000 International Fertility (IVF)* Expenses paid onbehalf Affiliate 4 15 H.C Security Provide service Entity owned byCompany's boardmember (17) (90) Life Health Care Provided service Entity owned byCompany's CEO 724 1,419 Dr. Amid Abd Elnour Put option liability Bio. Lab C.E.O andshareholder (65,574) (578,151) Current account Bio. Lab C.E.O andshareholder (10,491) (30,174) Share-basedpayment Bio. Lab C.E.O andshareholder (5,355) (5,355) International Financecorporation (IFC) Put option liability Echo-Scanshareholder (30,573) (50,494) Integrated Treatment for KidneyDiseases (S.A.E) Rental income Entity owned byCompany's CEO 2,019 - Medical Test analysis Entity owned byCompany's CEO 1,716 4,534 HENA HOLDINGS LTD shareholders'dividends deferralagreement Shareholder 4,879 - ACTIS IDH LIMITED shareholders'dividends deferralagreement Shareholder 4,019 - (658,296) *ALborg Scan is a company whose shareholders include Dr. Moamena Kamel (founder of IDH subsidiary AlMokhtabar Labs).** International Fertility (IVF) is a company whose shareholders include Dr. Moamena Kamel (founder of IDHsubsidiary Al-Mokhtabar Labs). 15. Related party transactions (continued) Compensation of key management personnel of the Group The amounts disclosed in the table are the amounts recognised as an expense during the reporting period related to keymanagement personnel. 30 June 2026 30 June 2025 (Unaudited) (Unaudited) Short-term employee benefits 67,750 64,231 67,750 64,231 16. General and administrative expenses For the six months ended 30 June 2026 2025 (Unaudited) (Unaudited) Wages and salaries 226,419 206,765 Depreciation 16,844 14,474 Amortisation 4,729 4,896 Consulting fees 97,525 53,516 Other expenses 107,517 112,953 Total 453,034 392,604
Page 23
17. Net fair value losses on financial assets at fair value through profit or loss During the first half of 2025, Integrated Diagnostics Holdings Limited company invested in Global Depositary Receipt (GDR)tradable in stock exchanges, where the companies purchased 2.740 million shares, EGP 55 M from the Egyptian Stock Exchangeand sold them during the same period on the London Stock exchange at USD 1.03 M excluding the transaction cost. Number ofshares'000 2026 2025 EGP'000 EGP'000 (Unaudited) (Unaudited) listed equity securities Shares bought 2,740 - (55,047)Shares sale 2,740 - 50,107- (4,940) 18. Net finance cost For the six months ended30 June 2026 2025 Finance income (Unaudited) (Unaudited) Interest income 109,671 107,363 Net foreign exchange gain 36,891 - Total finance income 146,562 107,363 Finance cost Net foreign exchange (loss) - (3,493) Bank charges (14,832) (11,293) Interest expense (135,150) (85,543) Total finance cost (149,982) (100,329) Net finance income (3,420) 7,034 19. Tax expense Tax expense is recognised based on management's best estimate of the weighted-average annual income tax rate expected forthe full financial year multiplied by the pre-tax income of the interim reporting period. A) Income tax Amounts recognised in profit or loss as follows: For the six months ended30 June 2026 2025 (Unaudited) (Unaudited)Current tax: Current tax (355,965) (267,449)Deferred tax: Deferred tax arising on undistributed reserves in subsidiaries (125,839) (66,852)Deferred tax relating to origination and reversal of temporary differences (777) (7,659)Total Deferred tax expense (126,616) (74,511) Tax expenses recognised in profit or loss (482,581) (341,960) B) Deferred tax liabilities Deferred tax relates to the following: 30 June2026 31 December2025 (Unaudited) (Audited) Property, plant and equipment (71,317) (70,225) Intangible assets (117,715) (117,919) Undistributed reserves from Group subsidiaries (462,156) (370,571)Provisions 61 61 Net deferred tax liabilities (651,127) (558,654) 20. Financial instruments The Group has reviewed the financial assets and liabilities held at 30 June 2026. It has been deemed that the carrying amountsfor all financial instruments are a reasonable approximation of fair value. All financial instruments are deemed Level 3. 21. Earnings per share For the six months ended30 June
Page 24
2026 2025 (Unaudited) (Unaudited) Profit attributed to owners of the parent 821,535 551,354 Weighted average number of ordinary shares in issue 581,326 581,326 Basic and diluted earnings per share 1.41 0.95 The Company has no potential diluted shares as at 30 June 2026 and 30 June 2025, therefore the earnings per diluted share areequivalent to basic earnings per share. 22. Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker who is responsible for allocating resources and assessing performance of theoperating segments, has been identified as the steering committee that makes strategic decisions. The Group has five operating segments based on geographical location, as the Group's Chief Operating Decision Maker (CODM)reviews the internal management reports and KPIs of each geography. The Group operates in five geographic areas, Egypt, Sudan, Jordan, Nigeria and Saudi Arabia. As a provider of medical diagnosticservices, IDH's operations in Sudan are not subject to sanctions. The revenue split, EBITDA split (being the key profit measurereviewed by CODM) net profit and loss between the five regions is set out below. 22. Segment reporting (continued) Revenue split by geographic location For the six months ended Egypt region Sudanregion Jordanregion Nigeriaregion SaudiArabia Total 30 June 2026 (Unaudited) 4,169,817 1,134 537,013 72,820 75,622 4,856,406 30 June 2025 (Unaudited) 2,965,813 1,451 492,535 57,562 25,327 3,542,688 Adjusted EBITDA by split geographic location For the six months ended Egypt region Sudanregion Jordanregion Nigeriaregion Saudi Arabia Total 30 June 2026 (Unaudited) 1,518,577 41 140,092 4,448 (15,876) 1,647,282 30 June 2025 (Unaudited) 1,072,046 (14) 141,767 1,347 (25,519) 1,189,627 Net profit / (loss) split by geographic location For the six months ended Egyptregion Sudanregion Jordanregion Nigeriaregion Saudi Arabia Total 30 June 2026 (Unaudited) 828,870 1,826 45,454 592 (37,596) 839,146 30 June 2025 (Unaudited) 554,246 20,650 48,366 (2,906) (49,062) 571,294 Non-current assets by geographic location Egypt region Sudanregion Jordanregion Nigeriaregion Saudi Arabia Total 30 June 2026 (Unaudited) 4,012,098 - 789,220 31,160 62,024 4,894,502 31 December 2025 3,757,154 - 784,762 28,217 73,239 4,643,372 The operating segment profit measure reported to the CODM is EBITDA, as follows: For the six months ended30 June 2026 2025 (Unaudited) (Unaudited) Profit from operations 1,325,147 911,160 Property, plant and equipment depreciation 201,530 160,198 Right of use depreciation 107,598 97,755 Amortization of Intangible assets 13,007 10,567 EBITDA 1,647,282 1,179,680 Non-recurring expenses - 9,947 Normalised EBITDA 1,647,282 1,189,627
Page 25
23. Post Balance Sheet Events: Hena Holdings Ltd, IDH's founding shareholder vehicle, which is wholly owned by IDH Chief Executive Officer Dr. Hend El-Sherbiniand her mother, Dr. Moamena Abdul Wahab Kamel, increased its shareholding in the Company during the period through amandatory cash offer. On 23 June 2026, Hena Holdings announced the offer following its acquisition of 126 million shares from Actis IDH Limited,representing 21.67% of IDH's total voting rights. The acquisition increased Hena Holdings' total ownership to 49.62%, triggering amandatory takeover offer under the UK Takeover Code. The initial offer period closed on 29 July 2026, followed by a final two-week extension, which expired on 12 August 2026. Following completion of the offer process and final settlements, HenaHoldings acquired additional shares through the offer, bringing its total ownership in IDH to 56.67%. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authorityto act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this informationmay apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the informationcontained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. Forfurther information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END